First Postpartum Depression Drug Fast Tracked and Licensed by FDA
![First Postpartum Depression Drug Fast Tracked and Licensed by FDA First Postpartum Depression Drug Fast Tracked and Licensed by FDA](https://thevaccinereaction.org/wp-content/uploads/2023/08/woman-and-baby.jpg)
On Aug. 4, 2023, the U.S. Food and Drug Administration (FDA) fast tracked licensure of the oral prescription medication Zurzuvae (zuranolone), manufactured by Sage Therapeutics, Inc. as a treatment for postpartum depression. Postpartum affects roughly one in seven women and typically begins after childbirth but, for some women, it can begin during later stages of […]